Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus TIP as neoadjuvant therapy for locally advanced penile cancer
ChiCTR2100054083Phase 2Recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Dec 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, paclitaxel, ifosfamide and cisplatin in penile cancer, sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: pathological complete response rate. Started Dec 2021; status: recruiting.
02
Drugs
camrelizumabpaclitaxelifosfamidecisplatin
03
Conditions
penile cancer
Beyond the preview
Go deeper on ChiCTR2100054083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054083.